Aflac Cancer Center and Blood Disorders Service
Emory University / Children's Healthcare of Atlanta

Faculty Publications – 2006
(N = 64)

Peer-Reviewed (N = 44)

1. Adamkiewicz TV, Boyer MW, Bray R, **Haight A**, Yeager AM. Identification of unrelated cord blood units for hematopoietic stem cell transplantation in children with sickle cell disease. *J Pediatr Hematol Oncol* 2006;28:29-32.

2. Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross, JA, Perentesis, **Woods WG**, Lange BJ, and Davies SM. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Blood* 2006;108:74-80.

3. Barredo JC, Devidas M, **Lauer SJ**, Billett A, Marymont MA, Pullen J, Camitta B, Winick N, Carroll W, Ritchey AK. Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study. *J Clin Oncol* 2006;24:3142-49.

4. Barrette S, Bernstein M, Leclerc J-M, Champagne M, Samson Y, Brossard J, and **Woods WG**. Treatment complications in children diagnosed with neuroblastoma during a screening program. *J Clin Oncol* 2006;24:1542-45.

5. Barrow R T, **Lollar P**. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII. *Journal of Thrombosis & Haemostasis* 2006;4:2223-9.

6. **Bennett CM**, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, **Abshire TC**, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, **Olson TA**, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Prospective phase ½ study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. *Blood* 2006;107:2639-42.

7. Berntorp E, **Abshire T**; von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept. *J Thromb Haemost* 2006;4:2511-2.

8. Denning G, **Durden DL,** Vogt PK. Nuclear localization as a mechanism for inhibiting the tumor suppressor properties of PTEN. *Oncogene* 2006;26:1-11.

9. Eapen M, Raetze, Zhang MJ, Muehlenbein C, Devidas M, **Abshire T**, Billett A, Homans A, Camitta B, Carroll WL and Davies SM for the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matches sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood* 2006;107:4961-7.

10. **Kempton CL**, Soucie JM and **Abshire TC**. Incidence of Inhibitors in a Cohort of 838 Males with Hemophilia A Previoiusly Treated with Factor VIII Concentrates. *J Thromb Haemost* 2006;4:2576-81.

11. Gangadharan B, Parker ET, Ide LM, **Spencer HT, Doering CB**. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. *Blood* 2006;107:3859-64.

12. Gow KW, Wulkan ML, Heiss KF, **Haight AE**, Heard ML, Rycus P, Fortenberry JD. Extracorporeal membrane oxygenation for support of children after hematopoietic stem cell transplantation: the Extracorporeal Life Support Organization experience. *J Pediatr Surg* 2006;41:662-7.

13. Gray T, Morrey EL, Gangadharan B, Sumter TF, Spychala J, **Archer DR, Spencer HT**. Enforced expression of cytosolic 5'-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection. *Cancer Chemother Pharmacol* 2006;58:117-28.

14. **Gu L**, **Findley HW**, Zhu N and **Zhou M**. Endogenous TNFα mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in childhood acute lymphoblastic leukemia cells. *Leukemia* 2006;20:900-4.

15. **Hendrickson JE,** Desmarets M, Deshpande S, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 2006;46(9):1526-1536.

16. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, McGlennen R, Smith FO, **Woods WG**, Salzer WL, Johnstone HS, Dreyer Z, and Reaman GH. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. *Blood* 2006;108:441-51.

17. Hillyer KL, Hare VW, **Josephson CD**, Harris SB, Hillyer CD. Partners for Life: the transfusion program for patients with sickle cell disease offered at the American Red Cross Blood Services, Southern Region, Atlanta, Georgia. I*mmunohematology* 2006;22:108-11.

18. **Kean L,** Gangappa S, Pearson T, and Larsen CP. Transplant Tolerance in Non-human Primates: Progress, Current Challenges and Unmet Needs. *Am J Transplant* 2006;6:884-93.

19. **Kean LS**, Adams AB, Strobert E, Hendrix R, Gangappa S, Jones TR, Shirasugi N, Rigby MR, Hamby K, Jiang J, Bello H, Anderson D, Cardona K, Durham MM, Pearson TC, and Larsen CP. Induction of Chimerism in Rhesus Macaques through Stem Cell Transplant and Costimulation Blockade-Based Immunosuppression. *Am J Transplant* 2006;7:320-35.

20. **Kean LS,** Hamby K, Koehn B, Lee E, Coley S, Stempora L, Adams A, Heiss E, Pearson T, Larsen CP. NK cells mediate costimulation-blockade resistant rejection of

allogeneic stem cells during nonmyeloablative transplantation. *Am J Transplant* 2006;6:292-304.

21. **Kempton CL**, Soucie JM, **Abshire TC**. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. *J Thromb Haemost* 2006;4:2576-81.

22. Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I, Anderson R, Desai S, McCusker P, Wu J, **Abshire T**, Mahoney D, Mitchell L. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. *Br J Haematol* 2006;134:526-31.

23. Kwiatkowski JL, Granger S, Brambilla DJ, **Brown RC**, Miller ST, Adams RJ; STOP Trial Investigators. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. *Br J Haematol* 2006;134:333-9.

24. Li Q, Li L, Shi W, Jiang X, Xu Y, Gong F, **Zhou M**, Edwards CK 3rd, Li Z. Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. *Cancer Immunol Immunother* 2006;55:1470-9.

25. Malogolowkin MH, **Katzenstein H**, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. *J Clin Oncol* 2006;20:2879-84.

26. Mannucci PM, **Abshire T**, Dimichele D, Santagostino E, Blanchette V. Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach. *Haemophilia* 2006;12:429-34.

27. Marks DI; Forman SJ; Blume KG; Perez WS; Weisdorf DJ, Keating A; Gale RP, Cairo MS, Copelan EA; **Horan JT**; Lazarus H; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; and Horowitz MM. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografts for acute lymphoblastic leukemia in first or second complete remission.the importance of the dose of total body irradiation. *Biol Blood Marrow Transplant* 2006;12:438-53.

28. McMillin DW, Hewes B, Gangadharan B, **Archer DR**, Mittler RS, **Spencer HT**. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. *Hum Gene Ther* 2006;17:798-806.

29. Parker ET, **Doering CB**, **Lollar P**. A1 Subunit-mediated regulation of thrombin-activated factor VIII A2 Subunit dissociation. *Journal of Biological Chemistry* 2006;281:13922-30.

30. Paulino AC, Ferenci MS, **Chiang KY**, Nowlan AW, Marcus RB Jr. Comparison of conventional to intensity modulated radiation therapy for abdominal neuroblastoma. *Pediatr Blood Cancer* 2006;46:739-744.

31. Peng XH, Karna P, Cao Z, Jiang BH, **Zhou M** and Yang L. Cross-talk between epidermal growth factor receptor and HIF-1 signal pathways increases resistance to apoptosis by upregulating survivin gene expression. *J Biol Chem* 2006;281:25903-14.

32. Percy MJ, Crowley LJ, **Boudreaux J**, Barber MJ. Expression of a Novel P275L Variant of NADH: Cytochrome b5 reductase gives functional insight to the conserved motif important for pyridine nucleotide binding. *Archives of Biochemistry and Biophysics* 2006;447:59-67.

33. Pollard J, Alonzo TA, Gerbing RB, **Woods WG**, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, and Meshinchi S. FLT3 internal tandem duplication in $CD34^{+}/CD33^{-}$ precursors predicts poor outcome in acute myeloid leukemia. *Blood* 2006;108:2764-69.

34. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, **Durden DL**, McNurlan MA, Wek RC, Anthony TA. Role of glutamine depletion in directing tissue specific nutrient stress responses to L-asparaginase. *J. Biol Chem* 2006;281:31212-33.

35. Rong Y, **Durden DL**, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiarmorphologic feature that links vascular pathology, hypoxia, and angiogenesis. *J Neuropathol Exp Neurol* 2006;65:529-39.

36. Rong, Y., Hu, F., Huang, R., Mackman, N., Horowitz, J., Jensen, R., **Durden, D.L**., VanMeir, E., Brat, D. DGR-1 regulates hypoxia-induced expression of tissue factor in glioblastoma through HIF-1 independent mechanisms., *Cancer Research* 2006;66:7067-74.

37. Shi W, Li L, Shi X, Zheng F, Zeng J, Jiang X, Gong F, **Zhou M**, Li Z. Inhibition of nuclear factor-kappaB activation is essential for membrane-associated TNF-alpha-induced apoptosis in HL-60 cells. *Immunol Cell Biol* 2006;84:366-73.

38. Wenger S, Grossfeld PD, Siu BL, Coad JE**, Keller FG**, Hummel MB. Molecular characterization of an 11q interstitial deletion in a patient with the clinical features of Jacobsen Syndrome. *American Journal of Medical Genetics* 2006;140:704-8.

39. Wittman B, **Horan, J**, Lyman, G. Prophylactic Colony-Stimulating Factors in Pediatric Patients Receiving Myelosuppressive Chemotherapy: A Meta-Analysis of Randomized Controlled Trials. *Cancer Treatment Reviews* 2006;32:289-303.

40. **Woods WG**. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. *Pediatr Blood Cancer* 2006;46:565-9.

41. **Zhou M.** Transcriptional regulation of survivin: new target for cancer treatment. *Current Cancer Therapy Reviews* 2006;2:331-9.

42. Zhou S, Wang GP, Liu C and **Zhou M**. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: Prognostic markers for breast cancer. *BioMed Central Cancer* 2006;6:231-43.

43. Zhu N, **Gu L**, **Findley HW**, Chen C, Dong J and **Zhou M**. Expression of KLF5 and its interaction with p53 in regulating survivin expression in acute lymphoblastic leukemia. *J Biol Chem* 2006;281:14711-8.

44. Zimring JC, Hair GA, Deshpande SS, **Horan JT**. Immunization to minor histocompatibility antigens on transfused RBC through crosspriming into recipient MHC class I pathways. *Blood* 2006;107:187-9.

Non-Peer Reviewed Publications (N= 20)

1. **Abshire TC.** Prophylaxis and von Willebrand's disease (vWD). *Thromb Res.* 2006;118 Suppl 1:S3-7

2. Arceci RJ, Burnett A, Estey E, Hills R, Phil D, and **Woods WG**. Acute myelogenous leukemia in adolescents and young adults: what is the optimal therapy. ASCO Education Book 2006;06:533-41.

3. Berntorp E, **Abshire T**; on behalf of the vWD PN steering committee. The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept. *Thromb Res*. 2006;118 Suppl 1:S19-22.

4. **Chiang KY**, Henslee-Downey PJ and Godder K. Partially Mismatched Related Donor Transplantation in Pediatric Hematopoietic Stem Cell Transplantation. By Ronald M Kline (ed), Informa Healthcare, New York, NY 2006.

5. **Dunn AL**, **Abshire TC**. Current issues in prophylactic therapy for persons with hemophilia. *Acta Haematol* 2006;115:162-71.

6. Eisenbrey AB, Eastlund T, Frizzo WL, **Josephson CD**, Linden JV, Shapiro AS, Wilson D. Guidelines for Managing Tissue Allografts in Hospitals (1st ed). AABB Press, Bethesda MD, 2006.

7. **Janss AJ**, Maptone T. Pineal Region Tumors in Children. In: Tonn, Wstphal, Rutka, Groosan, eds. Neuro-Oncology of CNS Tumors. Publisher Springer, Berlin, copyright 2006:491-8.

8. **Josephson CD**, **Abshire TC**. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophiliac A and B, and for von Willebrand disease. *Best Pract Res Clin Haematol*. 2006;19:35-49.

9. **Josephson CD,** Strauss RG: Transfusion of the Neonate and Pediatric Patient. In Hillyer CD, Silberstein LE, Ness PM, Anderson KC (2nd eds): Blood Banking and Transfusion Medicine. Churchill Livingstone, Philadelphia, PA. 2006:510 - 22.

10. Kaye C, Accurso F, LaFranchi S, **Lane PA**, Northrup H, Pang S, Hope N, Sonya P, Bradley S, Michele A for the Committee on Genetics, American Academy of Pediatrics. Newborn Screening Fact Sheets. *Pediatrics* 2006;118:e934.

11. **Kean L,** Arceci R, and **Woods WG.** Chapter 21: Acute Myeloid Leukemia, in *Pediatric Hematology*, Eds: Hann, I., Arceci, R., and Smith, O. Blackwell Publishing Ltd. 2006.

12. **Kean, LS**, Anderson, AR, Oliva VL, Stempora L, Rigby MR, Pearson TC and Larsen CP. Immune monitoring in non-human primate transplantation. A review of the "Non-human primate transplantation tolerance models: Immune Assays and Analysis Workshop" held in Atlanta, GA, September, 2005. *Transplantation Reviews* 2006;20:139-45.

13. **Kempton CL**, Harvey RD 3rd, Roberts HR. Related Articles, Links Novel therapeutic agents in the management of hemorrhage and thrombosis. Cardiovasc Hematol Agents *Med Chem* 2006;4:319-34.

14. **Lollar P**. Hemophilia and immunology at the crossroads. [Editorial] *Journal of Thrombosis & Haemostasis* 2006; 4:2170-1.

15. Meeks SL., **Josephson CD.** Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates. *Current Opinion in Hematology* 2006;13:457-61.

16. Meshinchi S, Arceci RJ, Sanders JE, Smith FO, **Woods WG**, Radich JP, and Alonzo TA. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. *Blood* 2006;108:400. (Letter to the Editor)

17. Van den Berg HM, **Dunn A**, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. *Haemophilia* 2006;12:159-168.

18. **Woods WG**. Commentary: Let's Try It One More, Once. *Pediatr Blood Cancer* 2006;46:271-2.

19. **Yang YM**. Megaloblastic Anemia, In: Burg FD, Ingelfinger JR, Polin RA, Gershon AA (eds), Current Pediatric Therapy, 18th Ed, W. B.. Saunders Company, 2006.

20. **Yang YM**, Wang IM: eds; Chinese translation of "Osler's A Way of Life and other Addresses", with Commentary and Annotations, edited by Hinohara S, Niki H with forward by McGovern J, Duke University Press", New Century Publishing, Taipei, Taiwan, 2006.